- Country: Italy
- Summary: Multicenter Phase Ii, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Satralizumab In Pediatric Patients With Duchenne Muscular Dystrophy (Shield Dmd)
- ITT Ref No: 105094178
- Deadline: 09 Aug 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.:
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tender Are Invited Multicenter Phase Ii, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Satralizumab In Pediatric Patients With Duchenne Muscular Dystrophy (Shield Dmd)
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMulticenter Phase Ii, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Satralizumab In Pediatric Patients With Duchenne Muscular Dystrophy (Shield Dmd) - Italy Tender
The IRCCS Istituto Neurologico Carlo Besta, a Government sector organization in Italy, has announced a new tender for Multicenter Phase Ii, Open-Label Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Satralizumab In Pediatric Patients With Duchenne Muscular Dystrophy (Shield Dmd). This tender is published on ItalyTenders under ITT Ref No: 105094178 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-08-09.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
